Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

NCT06429904 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Pancreatic Cancer

Interventions

DRUG: Nimotuzumab+ NALIRIFOX

Sponsor

Peking Union Medical College Hospital